Upper gastrointestinal bleeding associated with the use of NSAIDs: newer versus older agents JR Laporte, L Ibanez, X Vidal, L Vendrell, R Leone Drug safety 27, 411-420, 2004 | 640 | 2004 |
Principios de epidemiología del medicamento JR Laporte | 563 | 2007 |
Upper gastrointestinal bleeding in relation to previous use of analgesics and non-steroidal anti-inflammatory drugs JR Laporte, X Carne, X Vidal, V Moreno, J Juan The Lancet 337 (8733), 85-89, 1991 | 448 | 1991 |
Dose–response relationships between individual nonaspirin nonsteroidal anti‐inflammatory drugs (NANSAIDs) and serious upper gastrointestinal bleeding: a meta‐analysis based on … SC Lewis, MJS Langman, JR Laporte, JNS Matthews, MD Rawlins, ... British journal of clinical pharmacology 54 (3), 320-326, 2002 | 336 | 2002 |
Population-based drug-induced agranulocytosis L Ibáñez, X Vidal, E Ballarín, JR Laporte Archives of internal medicine 165 (8), 869-874, 2005 | 301 | 2005 |
Principios básicos de investigación clínica JR Laporte | 298 | 2006 |
Epidemiology of aplastic anemia: a prospective multicenter study E Montané, L Ibáñez, X Vidal, E Ballarín, R Puig, N García, JR Laporte Haematologica 93 (4), 518-523, 2008 | 293 | 2008 |
Estudios de utilización de medicamentos y de farmacovigilancia JR Laporte, G Tognoni Principios de epidemiología del medicamento 2 (1), 24, 1993 | 266 | 1993 |
Agranulocytosis associated with dipyrone (metamizol) L Ibanez, X Vidal, E Ballarín, JR Laporte European journal of clinical pharmacology 60, 821-829, 2005 | 243 | 2005 |
Preliminary efficacy and safety of an oromucosal standardized cannabis extract in chemotherapy‐induced nausea and vomiting M Duran, E Pérez, S Abanades, X Vidal, C Saura, M Majem, E Arriola, ... British journal of clinical pharmacology 70 (5), 656-663, 2010 | 211 | 2010 |
Upper gastrointestinal bleeding associated with antiplatelet drugs L Ibanez, X Vidal, L Vendrell, U Moretti, JR Laporte, ... Alimentary pharmacology & therapeutics 23 (2), 235-242, 2006 | 209 | 2006 |
Oral antispastic drugs in nonprogressive neurologic diseases: a systematic review E Montané, A Vallano, JR Laporte Neurology 63 (8), 1357-1363, 2004 | 180 | 2004 |
Drug utilization studies: a tool for determining the effectiveness of drug use. JR Laporte, M Porta, D Capella British journal of clinical pharmacology 16 (3), 301-304, 1983 | 176 | 1983 |
Prospective surveillance of acute serious liver disease unrelated to infectious, obstructive, or metabolic diseases: epidemiological and clinical features, and exposure to drugs L Ibáñez, E Pérez, X Vidal, JR Laporte Journal of hepatology 37 (5), 592-600, 2002 | 159 | 2002 |
Métodos aplicados en estudios descriptivos de utilización de medicamentos D Capellà, JR Laporte Principios de epidemiología del medicamento 2, 67-93, 1993 | 153 | 1993 |
Multicenter study on self‐medication and self‐prescription in six Latin American countries Drug Utilization Research Group, Latin America, ... Clinical Pharmacology & Therapeutics 61 (4), 488-493, 1997 | 150 | 1997 |
End‐stage renal disease and non‐narcotic analgesics: a case‐control study. M Morlans, JR Laporte, X Vidal, D Cabeza, PD Stolley British journal of clinical pharmacology 30 (5), 717-723, 1990 | 135 | 1990 |
β-Adrenergic blocking agents in heart failure: Benefits of vasodilating and nonvasodilating agents according to patients' characteristics: A meta-analysis of clinical trials S Bonet, A Agustí, JM Arnau, X Vidal, E Diogene, E Galve, JR Laporte Archives of Internal Medicine 160 (5), 621-627, 2000 | 134 | 2000 |
Bovine gangliosides and acute motor polyneuropathy A Figueras, FJ Morales-Olivas, D Capella, V Palop, JR Laporte BMJ: British Medical Journal 305 (6865), 1330, 1992 | 96 | 1992 |
Spontaneous reporting of adverse drug reactions to non-steroidal anti-inflammatory drugs: a report from the Spanish System of Pharmacovigilance, including an early analysis of … A Figueras, D Capella, JM Castel, JR Laporte European journal of clinical pharmacology 47, 297-303, 1994 | 95 | 1994 |